16 results
8-K
EX-99.1
RGEN
Repligen Corp.
12 Apr 23
Regulation FD Disclosure
7:31am
. biopharma o 22,000 sq. ft. o $7M base (non-COVID) revenue FY22 Base with some C&GT o 3 clean rooms (ISO Class 7) o $6-$8M base revenue FY23e o
8-K
EX-1.1
wzz25g ixv6dxq9oole
8 Dec 20
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
4:05pm
8-K
EX-10.1
r1ut mdy20
31 May 19
Entry into a Material Definitive Agreement
4:01pm
424B5
g9wkx u1tkmjokyv1hmz
1 May 19
Prospectus supplement for primary offering
4:08pm
424B5
zsh9 atzmkzt
29 Apr 19
Prospectus supplement for primary offering
4:40pm
- Prev
- 1
- Next